NMAD

-- -- --

From March 31,2026 to June 30,2026 Cancellation of shares Exercise of common warrants Exercise of pre-funded warrants Issuance of common stock and pre-funded warrants from public offering, net Stock-based compensation — incremental cost related to cancellation of options and issuance of restricted stock units Stock-based compensation — vesting of options

Common stock offered 2,366,503 shares by the company

From December 31,2025 to March 31,2026 Conversion of Series B Convertible Preferred Stock and related dividend Exercise of pre-funded warrants Fair value of shares issued for services

From December 31, 2024 to December 31, 2025 Conversion of Series A convertible stock Proceeds from sale of securities in July 2025 registered private placement, net of offering costs Proceeds from sale of securities in February 2025 registered direct offering, net of offering costs Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs Proceeds from sale of securities in December 2025 registered direct offering, net of offering costs Exercise of placement agent warrants Exercise of pre-funded warrants Exercise of common warrants Common stock issued for services Conversion of Series B Convertible Preferred Stock and related dividend Common stock issued for acquisition of Liora

Common Stock offered 526,342 shares by the company

From June 30, 2025 to September 30, 2025 Proceeds from sale of securities in July 2025 registered private placement, net of offering costs Proceeds from sale of securities in July 2025 registered direct offering, net of offering costs Exercise of placement agent warrants Exercise of pre-funded warrants Exercise of common warrants Shares issued for services

Common Stock offered 210,675 shares by the company

From March 31, 2025 to June 30, 2025 Conversion of Series A convertible preferred stock

From December 31, 2024 to March 31, 2025 Proceeds from sale of securities in registered direct offering, net of offering costs

Common Stock offered 434,784 shares by the company

From June 30, 2023 to September 30, 2023 Proceeds from sale of securities in registered direct offering, net of offering costs Exercise of pre-funded common stock warrants

Common Stock offered 180,000 shares by the company

Reverse Stock Split,1-for-10 split

From December 31, 2022 to March 31, 2023 Exercise of options

From March 31, 2022 to June 30, 2022 Proceeds from sale of common stock in direct equity offering, net of offering costs

1.Common stock outstanding prior to this offering 13,746,593 shares. 2.The number of shares of common stock to be outstanding after this offering as described above is based on 13,746,593 shares outstanding as of March 31, 2022.

From June 30, 2021 to September 30, 2021 Exercise of options

From March 31, 2021 to June 30, 2021 Exercise of options

From December 31, 2020 to March 31, 2021 Proceeds from sale of common stock in direct equity offering, net of offering costs Exercise of warrants

1.Common stock offered 1,133,102 shares. 2.The number of shares of common stock to be outstanding after this offering as shown above is based on 12,374,302 shares of common stock outstanding as of February 25, 2021.

from December 31, 2019 to December 31, 2020 Proceeds from sale of common stock units in public offering, net of offering costs Common stock issued for services